<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03953807</url>
  </required_header>
  <id_info>
    <org_study_id>CMO-MA-EYE-0603</org_study_id>
    <secondary_id>2018-004785-33</secondary_id>
    <nct_id>NCT03953807</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never Treated</brief_title>
  <official_title>A 12-month, Prospective, Open-label, Phase 4 Study to Evaluate the Efficacy and Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Treatment Naïve Patients (According to Standard Clinical Practice) With Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of OZURDEX in patients with Diabetic Macular
      Edema when used in a real world setting in Spain and Portugal.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 5, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in best corrected visual acuity (BCVA) 2 months (± 2 weeks) after the last injection</measure>
    <time_frame>Baseline, at Month 10 through 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in Central Retinal Thickness (CRT) 2 months (± 2 weeks) after the last injection received</measure>
    <time_frame>Baseline, at Month 10 through 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean retreatment interval in months</measure>
    <time_frame>During the 12 to 14-month study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) for CRT</measure>
    <time_frame>Baseline, During the 12 to 14-month study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC for BCVA</measure>
    <time_frame>Baseline, During the 12 to 14-month study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25)</measure>
    <time_frame>Baseline, at Month 14</time_frame>
    <description>25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better functioning. Original numeric values from the survey will be recoded with the worst and best possible scores set at 0 and 100 points, respectively. In this format, scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with 2nd injection</measure>
    <time_frame>During the 12 to 14-month study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with 3rd injection</measure>
    <time_frame>During the 12 to 14-month study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of injections administered</measure>
    <time_frame>During the 12- to 14-month study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 3rd injection</measure>
    <time_frame>During the 12 to 14-month study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 2nd injection</measure>
    <time_frame>During the 12 to 14-month study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Ozurdex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZURDEX implant 700 μg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone Intravitreal Implant</intervention_name>
    <description>Implant 700 μg</description>
    <arm_group_label>Ozurdex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Prior diagnosis of diabetes mellitus (type 1 or type 2)

          -  Media clarity, pupillary dilation, and patient cooperation sufficient for all study
             procedures

          -  Written informed consent obtained in accordance with all local privacy requirements

        Exclusion Criteria

          -  Uncontrolled systemic disease

          -  History of disease, metabolic dysfunction, or clinical laboratory finding giving
             reasonable suspicion of a disease condition that contraindicates the use of the
             investigational drug, might affect the interpretation of study results, or render the
             patient at high risk from treatment complications

          -  Patients who have been previously treated for DME (two focal laser allowed)

          -  Untreated diabetes or anticipated change (increase) of antidiabetic medications during
             the study

          -  Elevated IOP or glaucoma diagnosis

          -  Any active ocular infection or inflammation

          -  Aphakia

          -  A substantial cataract is present that is likely to be decreasing visual acuity by
             three lines or more (i.e., cataract would be reducing visual acuity to 20/40 or worse
             if the eye was otherwise normal)

          -  Anticipated need for ocular surgery during the study

          -  History of vitrectomy or incisional glaucoma surgery

          -  Female patients who are pregnant, nursing, or planning a pregnancy, or who are of
             childbearing potential and not using a reliable means of contraception

          -  Known allergy, hypersensitivity or contraindication to the study medication, its
             components, or povidone iodine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel Zaw</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Registry Team</last_name>
    <phone>877-277-8566</phone>
    <email>IR-CTRegistration@Allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHUC - Centro Hospitalar e Universitário de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Santo André - Centro Hospitalar de Leiria</name>
      <address>
        <city>Leiria</city>
        <zip>2410-197</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRL - Instituto de Retina e Diabetes Ocular de Lisboa</name>
      <address>
        <city>Lisboa</city>
        <zip>1050-085</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00 351 937255402</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Lisboa Norte - Hospital de Santa Maria</name>
      <address>
        <city>Lisbon</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de So Joo EPE</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Vila Franca de Xira</name>
      <address>
        <city>Vila Franca de Xira</city>
        <zip>2600-009</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>8021</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00 34 93 209 53 11 Ext. 313</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IMO</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0034 934 000 700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Cruces</name>
      <address>
        <city>Bilbao</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00 34 646 844 328</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Oftalmológico</name>
      <address>
        <city>Galicia</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0034 661 92 81 47</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oftalvist Madrid_HLA Universitario Moncloa</name>
      <address>
        <city>Madrid</city>
        <zip>28008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00 34 915957382</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oftalvist Moncloa</name>
      <address>
        <city>Madrid</city>
        <zip>28008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00 34 976556400 Ext. 4216</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vissum Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0034-630022127</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Son Espases</name>
      <address>
        <city>Palma</city>
        <zip>7120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0034 971 175 721</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clnica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00 34 948 296 331</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00 34 691 352 224</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00 34 9613 1886</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau Vilanova</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00 34 619 105 103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Araba</name>
      <address>
        <city>Vitoria</city>
        <zip>1004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00 34 619 621 634</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miguel Servet University Hospital</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0034 976765500 (ext 1089)</phone>
    </contact>
  </location>
  <location_countries>
    <country>Portugal</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.AllerganClinicalTrials.com</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact IR-CTRegistration@Allergan.com for assistance.</description>
  </link>
  <link>
    <url>http://www.investigatordatabank.org/</url>
    <description>To be considered as a site for current and future Allergan Clinical Trials, please register using the Investigator Databank link.</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 13, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2019</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Allergan will share de-identified patient-level data and study-level data including protocols and clinical study reports for phase 2 - 4 trials completed after 2008 that are registered to ClinicalTrials.gov or EudraCT, have received regulatory approval in the United States and/or the European Union in a given indication and the primary manuscript from the trial has been published. To request access to the data, the researcher must sign a data use agreement and any shared data is to be used for non-commercial purposes. More information can be found on http://www.allerganclinicaltrials.com/.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After having received regulatory approval in the United States and/or the European Union in a given indication and the primary manuscript from the trial has been published.</ipd_time_frame>
    <ipd_access_criteria>To request access to the data, the researcher must sign a data use agreement and any shared data is to be used for non-commercial purposes.</ipd_access_criteria>
    <ipd_url>http://www.allerganclinicaltrials.com/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

